Post-earnings recap
Reported
Thu, May 21, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Xenon Pharmaceutical reported a narrower loss than expected, which is a positive sign for investors. However, the stock fell by nearly 3% after the earnings report, indicating some investor caution. The lack of revenue figures and forward guidance may have contributed to the stock's decline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.22 | N/A | +29.71% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the company's progress in the quarter. They emphasized a commitment to advancing their drug pipeline.
We are pleased with our progress despite the challenges.
Our focus remains on advancing our pipeline.